Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04143425 (Prospective Observational Study of Imaging-based Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastomas), which is not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Observational Study of Imaging-based Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastomas
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysisDiagnostic and interventional radiology (Ankara, Turkey) · 2024Pooled it
- Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.Journal of neuro-oncology · 2022Pooled it
- Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis.AJNR. American journal of neuroradiology · 2022Pooled it
- Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.Neuro-oncology · 2020Trial
- Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.Journal of neuro-oncology · 2019Trial
- Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.Neuro-oncology · 2018Trial
- Imaging patterns of necrosis after treatment with chemoradiation are prognostic for survival in glioblastoma.European radiology · 2026Article
- Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.Journal of neuro-oncology · 2026Article
- Predictive value of apparent diffusion coefficient, plasma levels of placental growth factor and glial fibrillary acidic protein, and their combinations for patients with recurrent glioblastoma.Discover oncology · 2026Article
- Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker.Journal of neuro-oncology · 2025Article
- Early Tumor Shrinkage and Depth of Response as Predictive Markers of Treatment Response and Prognosis in Solid Tumors.Cancer medicine · 2025Review
- Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response.Journal of neuro-oncology · 2025Article
- Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma.CNS oncology · 2024Article
- The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker.Radiology · 2024Review
- Prognostic value of preoperative diffusion restriction in glioblastoma.La Tunisie medicale · 2024Article
- Small pretreatment lesion size and high sphericity as favorable prognostic factors after laser interstitial thermal therapy in brain metastases.Journal of neurosurgery · 2024Article
- Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Diagnostic Approaches to Adult-Type Diffuse Glial Tumors: Comparative Literature and Clinical Practice Study.Current oncology (Toronto, Ont.) · 2023Review
- Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.Signal transduction and targeted therapy · 2023Review
- Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.Neuro-oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. bellingson@mednet.ucla.edu.
Elizabeth R GerstnerMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Marion SmitsDepartment of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre Rotterdam, The Netherlands.
Raymond Y HuangDepartment of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
Rivka ColenDepartment of Neuroradiology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lauren E AbreyF. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Dana T AftabExelixis, South San Francisco, California.
Gisela M SchwabExelixis, South San Francisco, California.
Colin HesselExelixis, South San Francisco, California.
Robert J HarrisUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Ararat ChakhoyanUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Renske GahrmannDepartment of Radiology and Nuclear Medicine, Erasmus MC, University Medical Centre Rotterdam, The Netherlands.
Whitney B PopeDepartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Kevin LeuUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Davis C WoodworthUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
John de GrootDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.
Tracy T BatchelorMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Martin J van den BentDepartment of Neuro-Oncology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands.
Timothy F CloughesyUCLA Neuro Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Massachusetts General Hospital · US
Funding
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Linda M Liau · 2017 to 2026
$25.2MAZD2171 and chemoradiation for newly diagnosed glioblastomaR01CA129371 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BATCHELOR, TRACY T · 2007 to 2017
$6.2MClinical and Molecular Studies of Novel Therapeutics in Malignant Brain TumorsK24CA125440 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BATCHELOR, TRACY T · 2007 to 2016
$1.9MA Phase 2 study of AZD2171 in Recurrent GlioblastomaR21CA117079 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BATCHELOR, TRACY T · 2005 to 2006
$683kEPA EP-C-15-003NCI NIH HHS K24 CA125440NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA129371NCI NIH HHS R21 CA117079
Abstract
PubMed holds no abstract for this paper.
Indexed as
Angiogenesis InhibitorsAnilidesBevacizumabBiomarkers, TumorDiffusion Magnetic Resonance ImagingDisease-Free SurvivalFemaleGlioblastomaHumansIndolesLomustineMaleMiddle AgedNeoplasm Recurrence, LocalPyridinesQuinazolinesafliberceptAngiogenesis InhibitorsAnilidesBevacizumabBiomarkers, TumorcabozantinibcediranibIndolesLomustinePyridinesQuinazolinesReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AVEGFA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04143425ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.